Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Reeder

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
JNCI Cancer Spectrum|January 7, 2021
Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16</i>Shlomit S Shachar, Allison M Deal, Katherine E Reeder-Hayes, et al.
Trials|October 3, 2022
Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settingsStephanie B Wheeler, Caitlin B Biddell, Michelle L Manning, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 25, 2024
Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic StatusSarah C Van Alsten, Matthew R Dunn, Alina M Hamilton, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
Breast Cancer Research and Treatment|November 5, 2021
Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancerK A Nyrop, E M Damone, A M Deal, et al.
Cancer|November 20, 2020
Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancerKirsten A Nyrop, Allison M Deal, Yi Tang Chen, et al.
The Oncologist|December 16, 2018
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast CancerKirsten A Nyrop, Allison M Deal, Shlomit S Shachar, et al.
Cancer|May 16, 2019
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practiceKirsten A Nyrop, Allison M Deal, Kathryn E Reeder-Hayes, et al.
Cancer|April 22, 2020
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancerKirsten A Nyrop, Allison M Deal, Bryce B Reeve, et al.
Cancer Medicine|January 16, 2023
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effectsZev M Nakamura, Allison M Deal, Eliza M Park, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
JNCI Cancer Spectrum|January 7, 2021
Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16</i>Shlomit S Shachar, Allison M Deal, Katherine E Reeder-Hayes, et al.
Trials|October 3, 2022
Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settingsStephanie B Wheeler, Caitlin B Biddell, Michelle L Manning, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 25, 2024
Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic StatusSarah C Van Alsten, Matthew R Dunn, Alina M Hamilton, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
Breast Cancer Research and Treatment|November 5, 2021
Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancerK A Nyrop, E M Damone, A M Deal, et al.
Cancer|November 20, 2020
Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancerKirsten A Nyrop, Allison M Deal, Yi Tang Chen, et al.
The Oncologist|December 16, 2018
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast CancerKirsten A Nyrop, Allison M Deal, Shlomit S Shachar, et al.
Cancer|May 16, 2019
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practiceKirsten A Nyrop, Allison M Deal, Kathryn E Reeder-Hayes, et al.
Cancer|April 22, 2020
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancerKirsten A Nyrop, Allison M Deal, Bryce B Reeve, et al.
Cancer Medicine|January 16, 2023
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effectsZev M Nakamura, Allison M Deal, Eliza M Park, et al.
Pageof 23